What is the e-cigarette trend among your patients who smoke?
Topical PDE4 Inhibitor ZORYVE® (Roflumilast) Cream for the Treatment of Atopic Dermatitis
May 7th 2025ZORYVE® (roflumilast) cream 0.15% is a once-daily, steroid-free PDE4 inhibitor approved for the treatment of mild to moderate atopic dermatitis in patients aged 6 and older. Clinical trials demonstrate its rapid onset, strong efficacy, and favorable safety profile, with emerging evidence supporting its use in younger children and as a long-term maintenance therapy to prevent flares.